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Abstract
Pancreatic cancer is a largely incurable disease, and increasing evidence supports strategies targeting multiple molecular
mediators of critical functions of pancreatic ductal adenocarcinoma cells. Intracellular redox state modulates the activity of
various signal transduction pathways and biological processes, including cell survival, drug resistance and responsiveness to
microenvironmental factors. Recently, it has been shown that the transcription factor STAT3 is under redox control, but the
mechanisms involved in its regulation are unknown. Here, we demonstrate for the first time that STAT3 DNA binding and
transcriptional activity is directly regulated by the redox function of the APE1/Ref-1 endonuclease, using overexpression and
redox-specific mutational strategies, and gene knockdown. Also, pharmacological blockade of APE1/Ref-1 by the redox-
selective inhibitor E3330 abrogates STAT3 DNA binding. Since APE1/Ref-1 also exerts redox control on other cancer-
associated transcription factors, we assessed the impact of dual-targeting of STAT3 signaling and APE1/Ref-1 redox on
pancreatic cancer cell functions. We observed that disruption of APE1/Ref-1 redox activity synergizes with STAT3 blockade
to potently inhibit the proliferation and viability of human PDAC cells. Mechanistically, we show that STAT3–APE1/Ref-1 dual
targeting promotes marked tumor cell apoptosis, with engagement of caspase-3 signaling, which are significantly increased
in comparison to the effects triggered by single target blockade. Also, we show that STAT3–APE1/Ref-1 dual blockade
results in significant inhibition of tumor cell migration. Overall, this work demonstrates that the transcriptional activity of
STAT3 is directly regulated by the redox function of APE1/Ref-1, and that concurrent blockade of STAT3 and APE1/Ref-1
redox synergize effectively inhibit critical PDAC cell functions.
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Introduction
Pancreatic cancer remains a largely incurable disease, with
patients facing the worst 5-year survival rate of any cancer. The
challenge is to identify molecular effectors that critically regulate
the survival of pancreatic ductal adenocarcinoma (PDAC) cells, to
devise effective molecular-targeted strategies that can prevent or
minimize the selection of resistant tumor variants, and overcome
the protective role of the tumor-associated fibrosis and stroma.
Increasing evidence supports the need for strategies targeting
multiple molecular effectors in PDAC. Thus, a strategy is to
identify critical molecules that regulate multiple signaling media-
tors (as transcription factors) and intracellular mechanisms with
direct effects on multiple pathways critical for PDAC functions.
APE1/Ref-1 (hereafter referred to as APE1) is a dual function
protein, which in addition to DNA repair activity also exerts redox
control of transcription factors, including NF-kB, p53, AP-1, HIF-
1 and others [1,2]. Treatment with E3330, a small molecule redox
signaling inhibitor that recognizes an alternate, redox active
conformation of APE1 [3] markedly inhibits the DNA binding and
transcriptional activity of NF-B, AP-1, and HIF-1 [4,5].
Functioning as a redox factor, APE1 stimulates the DNA binding
activity of transcription factors by reducing cysteine residues in the
DNA binding domain of the ‘target’ transcription factor. [6] While
the organism possesses general reduction-oxidation systems
(thioredoxin and glutaredoxin/glutathione), [7,8] APE1 functions
differently as it selectively regulates factors that directly govern
critical cellular functions, including hypoxia, DNA repair, in-
flammation, and angiogenesis. [4,9,10] Our previous work
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established APE1 as a potential molecular target in PDAC, by
demonstrating that human adenocarcinoma and peri-pancreatic
metastases exhibit increased APE1 expression [11], and that
blockade of APE1 redox activity delays tumor progression in
xenograft models of human PDAC, including patient-derived
tumor cells [4].
STAT3 is a transcription factor that regulates critical cell
functions and plays important roles in several cancers [12–15].
STAT3 signaling has been implicated in pancreatic cancer
biology, namely by mediating or regulating cell survival, tumor
angiogenesis and metastasis [16–18]. Although STAT3 signaling
can be engaged and modulated by different processes, the impact
of oxidative stress and its redox status are largely unknown. A
recent report demonstrated that STAT3 activity is under redox
control and identified the critical oxidation-sensitive cysteines in
the STAT3 DNA binding domain [19,20]. However, the modifier
of STAT3 which converts it from an oxidized into a reduced form
has not been identified. APE1 physically interacts with STAT3 on
the VEGF promoter [21] and enhances IL-6-induced DNA
binding activity of STAT3 in HepG2 cells [22]. However, it is
unknown whether APE1 is involved in the redox control of
STAT3 activity, and whether the cellular redox status affects
STAT3 signaling in PDAC cells.
Here, we demonstrate that APE1 redox activity regulates
STAT3 DNA binding and transcriptional activity, using gene
silencing, overexpression of WT or redox-defective APE1, and
redox-selective pharmacological inhibition. Blockade of APE1
redox synergizes with STAT3 selective antagonists to markedly
inhibit the proliferation and survival of human PDAC cells,
promoting cell apoptosis. These studies identify the mechanism by
which APE1 regulates STAT3 activity, and establishes the
rationale for the development of APE1– STAT3 dual-targeting
strategies for the treatment of PDAC.
Results
Redox Control of STAT3 Activity in PDAC Cells
Although STAT3 DNA binding is reportedly under redox
control [20], the molecular mechanism mediating this regulation is
unknown. Here, we investigated whether APE1 regulates the DNA
binding and transcriptional activities of STAT3 in PDAC. We
confirmed activation of STAT3 signaling using immunoblotting
and EMSA (Figure 1A, B). Both patient-derived and immortalized
cell lines express APE1and exhibit STAT3 phosphorylation
(residue Y705) and DNA binding; as expected, STAT3 DNA
binding is enhanced following stimulation with IL-6. To confirm
the specificity of STAT3 DNA binding, we performed EMSA
competition assays using cold DNA probes (WT or mutant,
STAT3-binding-defective sequences). As shown in Figure 1C,
a dose-dependent decrease in STAT3 DNA binding was observed
using the WT competitor probe which wasn’t observed using the
mutant probe. Specificity of this interaction was also demonstrated
by a supershift band observed using a STAT3-specific antibody
(Figure 1D).
We investigated the effects of oxidizing and reducing conditions
on STAT3 binding to DNA as well as its putative regulation by
APE1, using PDAC nuclear extracts and treatment with diamide
or DTT. Oxidizing conditions (diamide) abrogate the binding of
STAT3 to DNA (Figure 1E, F); in contrast, nuclear extracts
treated with the reducing agent DTT showed enhanced STAT3
DNA binding in a dose-dependent manner (Figure 1E; 1.4 to 2-
fold increase). Since the redox status of STAT3 affects its DNA
binding activity, we then evaluated whether the redox function of
APE1 modulates its DNA binding. Addition of reduced APE1
protein to PaCa-2 nuclear extracts increased STAT3 DNA
binding 1.8-fold (Figure 1G). As controls, we demonstrated that
unreduced APE1 and carry-over DTT from the reduction of
APE1 (0.04 mM) do not stimulate STAT3 DNA binding. These
studies indicate that STAT3 signaling is activated in PDAC, and
that STAT3 binding to DNA is redox sensitive and is regulated by
APE1.
STAT3 Transcriptional Activity is Increased by APE1
Overexpression and is Inhibited by APE1 Knockdown
Due to the multifunctional nature of APE1 with both DNA
repair and redox activities, we performed experiments to further
demonstrate that APE1 and its redox function is required for
STAT3 DNA binding and activity. Using lentiviral transcriptional
reporter vector, pGreenFire-STAT3-Luc (pGF-STAT3-Luc) and
pGreenFire-mCMV (negative control), from System Biosciences
Inc. (Mountainview, CA), we generated stably expressing reporter
cell lines to assay for STAT3 activity, similar to constructs used in
previous studies with NF-kB, AP-1, and HIF-1 [4]. Panc-1 cells
were transduced with pGF-STAT3-Luc, and single colonies were
screened for basal STAT3 and IL-6-stimulated STAT3 activity.
PDAC cells expressing STAT3-driven luciferase were transfected
to transiently overexpress wtAPE1 or the redox-defective mutant
C65A-APE1 (C65A). Overexpression of wtAPE1 stimulates the
activity of STAT3 in both clones (,3-fold), an effect that was not
seen in cells expressing the redox-dead APE1 mutant (Figure 2A).
In overexpression experiments in Figure 2A, single colonies were
assayed for luciferase activity after transient transfection with
pcDNA, pcDNA-wt-APE1, and pcDNA-C65A-APE1, and the
normalization was done using Renilla as a transfection control.
Knockdown of APE1 does not Affect Total STAT3 Protein
Levels, the STAT3 Phosphorylation or Nuclear
Translocation
We then assessed the impact of APE1 knockdown on STAT3
activity in PDAC cells. As above, single colonies of pGF-STAT3-
Luc were transiently transfected with APE1 siRNA for the
experiments shown in Figure 2B. Results from pGF-STAT3-Luc
clones#3 and#9 were pooled in experiments shown in Figure 2B
with representative experiments for each clone shown in Figure
S1A, B. Basal levels of STAT3 activity are significantly diminished
when APE1 expression is knocked down using transient, specific
siRNA (Figure 2B; p,0.001). The decrease in STAT3 activity by
APE1 knockdown was more pronounced in cells stimulated with
IL-6, further supporting a regulatory role for APE1 in the DNA
binding activity of STAT3 (Figure 2B, p,0.05; and Figures S1A,
B). The effects on STAT3 transcriptional activity when APE1
levels are decreased are not due to an increase in total STAT3
protein as shown by immunoblotting for total STAT3 protein
(Figure 2C and quantitation of blots in Figure S1C) and by qPCR
for STAT3 mRNA (Figure S1D). We also performed studies to
show that the impact of APE1 on STAT3 signaling was restricted
to the regulation of its DNA binding activity, and did not affect
levels of STAT3 phosphorylation (Figure 2D and quantitation in
Figure S1E). Furthermore, stimulation with IL-6 under conditions
of APE1 knockdown did not affect total STAT3 protein levels
(Figure 2E). As expected, stimulation with IL-6 increases the levels
of p-STAT3, and this regulation of STAT3 activity is not
dependent upon APE1 protein levels.
Next, we investigated the nuclear translocation of STAT3 by
probing lysates from nuclei and cytoplasm of PaCa-2 cells
transfected with APE1 siRNA or SC control; total STAT3 and
phospho-STAT3 (Y705) were analyzed, with tubulin and Lamin B
APE1/Ref-1 - STAT3 Interplay in Pancreatic Cancer
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used as cytoplasmic and nuclear controls, respectively. As
expected, stimulation with IL-6 resulted in marked increase in
the levels of p-STAT3 (Fig. 2E, F). Normalization of p-STAT3 to
Lamin B levels showed that there were no significant differences in
nuclear p-STAT3 in the APE1-silenced versus SC control (0.83
fold change). This finding was confirmed both in whole cell
extracts (Figure 2 D, E) and in nuclear extracts (Figure 2F). These
observations further indicate that APE1 regulates STAT3 DNA
binding without affecting other mechanisms of regulation, i.e.
phosphorylation, nuclear translocation, or amount of total STAT3
protein under basal or IL-6-induced conditions.
APE1 Redox Inhibitor, E3330 Inhibits STAT3
Transcriptional Activity
To more specifically address the role of the redox function of
APE1 on STAT3 transcriptional activity, we performed experi-
ments using the small molecule E3330, which selectively inhibits
APE1 redox activity without affecting its endonuclease function.
[3,5] E3330 markedly inhibits STAT3 activity both in stable lines
(Figure 3A; Figures S2A,B) as well as in transient luciferase assays
(Figure S2C). Basal STAT3 activity was significantly inhibited by
E3330 (Figure 3A; p,0.05) in a dose-dependent manner. Also,
E3330 treatment significantly inhibited the STAT3 activity
induced by IL-6 stimulation of PDAC cells (Figure 3A; p,0.05),
which was abrogated at higher E3330 doses. This inhibition of
STAT3 activity was not due to a decrease in total STAT3 protein
levels or a reduction in p-STAT3 levels. Results from immuno-
blotting of whole cell lysates demonstrated that the amount of
STAT3 protein and phosphorylated STAT3 protein (0.95-fold
compared to DMSO control) after treatment with APE1 redox
inhibitor, E3330 in PaCa-2 cells was not significantly changed
(Figure 3B).
To further confirm the inhibition of STAT3 DNA binding by
APE1 redox blockade, nuclear extracts from PaCa-2 cells were
treated with E3330 and analyzed by EMSA for STAT3 binding;
a dose-dependent decrease in STAT3 binding was observed
(Figure 3C), with an IC50 for E3330 around 30 mM (Figure 3D).
We also treated PaCa-2 cells with E3330 and then stimulated
STAT3 DNA binding with IL-6 and assayed for STAT3 DNA
binding using EMSA assay. As shown in Figure 3E and F, IL-6-
induced STAT3 activity is inhibited dramatically following E3330
treatment in cells. Further supporting a decrease in STAT3 DNA
Figure 1. STAT3 is under APE1 redox control in PDAC cells. A) Immunoblotting for STAT3 (pY705) in PDAC cells; total STAT3 levels shown in
middle panel. APE1 protein levels are shown for the patient-derived lines and tubulin is the loading control. B) STAT3 EMSA assay in PaCa-2 cells
stimulated with IL-6, NE = nuclear extract; C) Competitive EMSA on STAT3 using nuclear extract from PaCa-2 cells and either 25- or 50-fold cold
probe (WT or STAT3 binding-defective mutant); D) Supershift of STAT3 DNA binding using nuclear extract; E) STAT3 EMSA assay following treatment
with DTT and diamide. F) STAT3 EMSA assay following treatment with DTT or increasing concentrations of diamide, as indicated. G) STAT3 EMSA
assay with reduced APE1. DTT (Carry-over) reflects 0.04 mM DTT as used in the reaction after reducing the APE1 protein. For all EMSA assays, nuclear
extract from PaCa-2 cells was treated with IL-6 (50 ng/mL) for 2 hrs in 2% FBS, unless otherwise indicated.
doi:10.1371/journal.pone.0047462.g001
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binding following inhibition of APE1 redox activity, expression of
STAT3 target gene, Survivin is decreased in a dose-dependent
manner both in patient-derived cells (Figure 3G) and in PaCa-2
cells (Figure S2D). These studies demonstrate that manipulation of
APE1 expression and disruption of its redox function markedly
affects STAT3 DNA binding and transcriptional activity.
Pharmacologic Blockade of APE1 and STAT3 Results in
Synergistic Effects on Human PDAC Cells
First we show that treatment with two previously described
STAT3 antagonists, STATTIC [23] and S3I-201 [24] inhibited
phosphorylation of STAT3 (Figure 4 A,B) as well as cellular
proliferation in PDAC cells (Figure 4C). Statistically significant
inhibition of phosphorylation of Y705 is observed at doses of S3I-
201 greater than 100 mM and with doses of STATTIC greater
than 3.125 mM, as assessed by densitometry (p,0.05). At the
inhibitory doses tested, these compounds did not affect the
phosphorylation levels of STAT1 (Y701) or STAT5 (Y694) in
these cells (Figure 4A,B). Functional studies using the MTS assay
showed that STAT3 blockade markedly inhibits proliferation of
both PDAC lines (Figure 4C), with ED50 of ,2.5 mM for PaCa-2
and ,4 mM for Panc-1 for STATTIC, and ED50 ,190 mM for
Figure 2. Effects of modulation of APE1 expression on STAT3 transactivation in PDAC cells. A) Panc-1 cells transiently transfected with
pcDNA3, pcDNA3-wt-APE1, or pcDNA3-C65A-APE1 were assayed for STAT3 activity via luciferase reporter assay at 30 hr post-transfection. **p,0.01,
n = 3 for each clone comparing wt to C65A. B) STAT3 Reporter assay of Panc-1 cells transfected with scrambled or APE1 siRNA (50 nM) and stimulated
with IL-6 (50 ng/mL, 6 hr). * p,0.05, **p,0.01, n = 6 comparing SC to siAPE1. C) Western blot of total STAT3 protein levels following APE1
knockdown in PaCa-2 cells. Tubulin was used as a loading control. D) p-STAT3 (Y705) levels following APE1 knockdown in PaCa-2 cells. E)
Immunoblots of whole cell extracts showing that stimulation with IL-6 (50 ng/mL, 3 hrs) increases p-STAT3 levels in both SC- and siAPE1- treated cells
but does not change the levels of total STAT3 protein. F) Western blot of fractionated PaCa-2 cells stimulated with IL-6 and transfected with siRNA:
nuclear (N) and cytoplasmic (C) fractions. Tubulin was utilized as a loading control for cytoplasm and Lamin B1 for nuclear.
doi:10.1371/journal.pone.0047462.g002
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PaCa-2 and ,310 mM for Panc-1 for S3I-201. For both drugs,
a strong association was observed between decrease in STAT3
phosphorylation and inhibition of proliferation of PDAC cells.
In addition to regulating the transcriptional activity of STAT3,
APE1 also exerts redox control of other transcription factors,
which have been implicated in pancreatic cancer (such as HIF-1a
and NF-kB). [4,16,25] We then evaluated whether the combined
blockade of STAT3 and APE1 redox activity synergize to more
effectively inhibit human PDAC cells. Cell survival was assessed
using the xCELLigence system, which monitors real-time changes
in cell adherence, morphology and viability; [4,26] cell index (CI)
was monitored over 72 h drug treatment. E3330 was used at doses
that effectively inhibit APE1 redox activity, and STAT3 inhibitors
at doses that were utilized in the MTS-based assay for cytotoxicity
(Figure 4C) and that inhibited STAT3 phosphorylation in PDAC
cells (Figure 4A,B and Ref. [24]). As single agents, minimal
inhibition of PDAC cells was observed with E3330 or at the doses
of STATTIC or S3I-201 used (Figure 4D,E). We observed that
APE1 redox inhibition by E3330 synergizes with STAT3 blockade
by STATTIC or S3I-201, resulting in potent inhibition of Panc-1
and PaCa-2 cells, but also of the primary Pa03C and Panc10.05
cells (Figure 4D,E). The potentiation of the inhibitory effects seen
with this dual targeting, at sub-optimal doses of these agents, was
observed both using xCELLigence (Figure 4) and MTS assays
(Figure S3). Interestingly, in the patient-derived cells Pa03C and
Panc10.05, this enhancement was observed at lower doses of
E3330 than those observed with the established cells lines (data not
shown). Blockade of signaling through both APE1 redox activity
and STAT3 has dramatic effects on cell survival. To demonstrate
that this effect was not due to a general redox phenomenon, we
also combined STAT3 inhibitors with thioredoxin inhibitor, PX-
12 [27–29]. Addition of STAT3 inhibitor S3I-201 to PX-12
treatment did not significantly enhance the effects of PX-12 (Table
S1; assessed by comparison of ED25, ED50, and ED75).
Figure 3. STAT3 activity following treatment of PDAC cells with APE1 redox inhibitor, E3330. A) STAT3 reporter assay in Panc-1 cells
following treatment with E3330 (24 h) and stimulation with IL-6 (6 h). Doses were based on survival data from previously published data [4]. * p,0.05
t test, n = 6 comparing DMSO control to drug-treated samples. B) Representative Western blot of PaCa-2 cells treated with E3330 (50 mM, 24 hr). C)
Addition of E3330 to the EMSA reaction inhibits the STAT3 DNA binding of nuclear extracts stimulated with IL-6. Representative EMSA blot shown
with quantitation of three independent experiments in D. * p,0.05, ** p,0.01, compared to DMSO control, using Student’s t test. E) STAT3 DNA
binding via EMSA assay following treatment of PaCa-2 cells with E3330 (2 h) and then stimulated with IL-6 (50 ng/mL, 2 h) with quantitation in (F)
where intensity of binding was compared to amount of STAT3 DNA binding with IL-6 stimulation; G) qPCR analysis of Survivin expression following
E3330 treatment for 24 h in patient-derived cells, Pa02C. Shown is data from 2–3 individual experiments (avg6SE). Samples were run in triplicate and
normalized to DMSO vehicle control.
doi:10.1371/journal.pone.0047462.g003
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To quantify potential drug synergisms, the Chou-Talalay
method was used with increasing dose combinations of one
STAT3 antagonist plus the APE1 inhibitor E3330. The ED50 for
the three compounds was determined as shown above, using MTS
assays (Figure 4 and Ref. [4]). Panc-1 or PaCa-2 cells were treated
with two-drug combinations at fixed ratio of doses corresponding
to 0.125, 0.25, 0.5, 0.75, 1, 1.125, and 1.25-fold of their individual
ED50 values. As shown in Figure 4F, potent synergisms were
observed with combination index values significantly ,1 for ED50
and ED75 in both cell lines. Overall, these studies show that the
simultaneous targeting of APE1 redox and STAT3 signaling
synergize to markedly impair the survival of human pancreatic
cancer cells, even at sub-optimal doses of the individual agents.
Dual Targeting of APE1 Redox Activity and STAT3
Triggers Increase Apoptotic Effects in PDAC Cells
Subsequently, we performed mechanistic studies to examine
whether these synergistic effects involve increased apoptotic cell
death and engagement of the Caspase pathway. First, we used the
Annexin-PE/7-AAD assay to assess cell death and viability in
PDAC cells treated with the drug combinations indicated
(Figure 5A,C). Panels A and B depict representative plots of the
flow cytometry analyses, and show that the combination of E3330
with a STAT3 inhibitor markedly increase the frequency of
Annexin-positive, non-viable cells; comparable results were seen
for patient-derived cells (Figure 5B, D). Analyses of data from 4 to
6 individual experiments demonstrate that the combination of
E3330 with STATTIC or with S3I-201 significantly increases
pancreatic cancer cell death (Figure 5B). Furthermore, similar
results are observed in the patient-derived cells in which a ,6-8-
fold increase in cell death is observed with the combined targeting
of APE1 and STAT3 (Figure 5B,D).
To evaluate the potential involvement of caspase-dependent cell
death, we performed experiments measuring the activation of
caspase 3 in PDAC cells treated with the same drug combinations,
using a FITC-conjugated caspase-3 inhibitor (FITC-DEVD-FMK)
and flow cytometry. As shown in Figure 6, although single agents
did not induce marked caspase 3 activation, the combinatory
effects of APE1 redox inhibition and STAT3 blockade resulted in
substantial activation of caspase 3, in both PDAC cell lines
(Figure 6A,B, representative flow histograms in left panels). These
effects were statistically significant (Figure 6B; right panels) when
Figure 4. STAT3– APE1 dual targeting effectively inhibits PDAC cell proliferation. Immunoblotting of STAT proteins, p-STAT3(Y705), p-
STAT1(Y701), and p-STAT5(Y694) in PDAC cells treated with S3I-201 (A) or STATTIC (B). DMSO was used as vehicle control and is included in the lane
without STAT3 inhibitor. Panc-1 cells were treated with S3I-201 for 30 hr and STATTIC for 30 min. PaCa-2 cells were treated with S3I-201 and STATTIC
for 24 hr. C) Dose response in PaCa-2 and Panc-1 cells following 72 hr treatment with S3I-201 or STATTIC via MTS assay. D, E) Cell proliferation after
E3330 (50 mM for all lines, except 40 mM for Panc10.05) and S3I-201 or STATTIC treatment. Assays were performed in duplicate, representative
experiment, from 2–4 independent experiments. F) Combination index (CI) values calculated with Calcusyn for combination of APE1 and STAT3
inhibitors at their ED50s in the MTS assay. CI values of ,0.1, very strong synergy; 0.1–0.3: strong synergy; and 0.3–0.7: synergy.
doi:10.1371/journal.pone.0047462.g004
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E3330 was combined with STATTIC (A, p,0.05) or with S3I-201
(B, p,0.05). Overall, these results show that by combining sub-
optimal doses of individual selective agents, the simultaneous
targeting of APE1 redox and STAT3 signaling results in significant
cell death of PDAC cells, with the engagement of caspase 3 pro-
apoptotic effects.
Dual Targeting of APE1 Redox and STAT3 Signaling
Significantly Inhibits the Migration of PDAC Cells
Finally, since cell migration represents an important step in the
progression and dissemination of pancreatic cancer, we evaluated
the effects of APE1 and STAT3 blockade on the response of
PDAC cells to chemotactic stimuli, using the xCELLigence
system. Serum-deprived Panc-1 cells were placed in upper
chamber of a CIM plate, and stimulated with media supplemented
with serum, which provides chemotactic stimuli (lower chamber).
As expected, serum-starved Panc-1 cells do not migrate in the
absence of chemotactic stimuli, and fibronectin coating helps the
attachment of migrating cells (Figure S4A). Treatment of Panc-1
cells with E3330, STATTIC or S3I-201 as single agents resulted in
limited inhibition of Panc-1 cell migration, even at relatively high
doses of these compounds (Figure 7). However, combination of
E3330 with S3I-201 (50 mM and 100 mM, Fig. S4D) or with
STATTIC resulted in markedly decreased cell migration
(Figure 7D,E), with both S3I-201/E3330 and STATTIC/E3330
combinations resulting in significant inhibitory effects in Panc-1
cell migration (Figure 7F, Figure S4D, p,0.01; Figure 6G,
p,0.05 in comparison to E3330 alone and p,0.01 in comparison
to STATTIC alone). Importantly, these drugs or combinations
showed no significant effects on the viability of Panc-1 cells at the
timepoints and doses assessed in the migration assays (Figure S4
B,C). These results indicate that concurrent blockade of APE1
redox and STAT3 signaling cooperates also to inhibit the
migration properties of PDAC cells.
Discussion
In this report, we demonstrate for the first time that STAT3
DNA binding is under redox control, which is mediated by the
redox activity of APE1. Previous studies demonstrated that
oxidation of critical cysteines residues in STAT3 protein through
peroxide treatment could decrease STAT3 (but not STAT1) DNA
binding and transcriptional activity [20]. Using nuclear extracts
from PDAC cells, we systematically characterized the effects of
Figure 5. Effect on apoptosis of inhibition of APE1 in combination with STAT3 inhibitors in Panc-1, PaCa-2, and the patient-derived
Pa03C and Panc10.05 cells. Inhibitors were added simultaneously (E3330 40, 50, or 75 mM), and apoptosis was determined using Annexin-V (x-
axis) and 7-AAD or PI (y-axis) staining after 24 hr. Representative dot plots are shown in A and B with high dose of STAT3 inhibitor for Panc-1 and
PaCa-2 and 50mMS3I-201 for the patient-derived cells. Graphical representation represents .3 independent experiments; *, p,0.05, **, p,0.01 all
compared to STAT3 inhibitor alone at corresponding dose (A, C) or 2 independent experiments for (B, D).
doi:10.1371/journal.pone.0047462.g005
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reducing and oxidizing conditions on STAT3 DNA binding.
Clearly, STAT3 binds to DNA more effectively when is reduced,
and the redox activity of APE1 is capable of stimulating STAT3
DNA binding. Furthermore, manipulation of APE1 levels affects
the DNA binding activity of STAT3. The concurrent blockade of
STAT3 and APE1 redox activity acts synergistically to disrupt
PDAC cell viability as well as their migration properties.
This is the first demonstration also that APE1 regulates the
STAT3 DNA binding and transcriptional activity in PDAC cells.
This finding points to the interaction of APE1 and STAT3 as part
of the survival signaling in PDAC rather than a non-specific effect
of general redox regulators. Overexpression of a redox-deficient
APE1 protein failed to promote STAT3 transactivation in PDAC
cells, and blockade of the redox function of APE1 via E3330
dramatically inhibited the transcriptional activity of STAT3, both
basal levels as well as IL-6-induced activity. However, knockdown
of APE1 decreases STAT3 activity without affecting its phosphor-
ylation or nuclear translocation. Taken together, these data
support the hypothesis that APE1 directly controls the DNA
binding activity of STAT3. With the high levels of APE1
expression in PDAC tumors (Figure 1A, Ref. [11]), stimulation
of STAT3 signaling through APE1’s redox activity may contribute
to the threshold of STAT3 activity in the tumor leading to a more
aggressive phenotype. Increase in STAT3 signal fitness through
oncogenic events and/or tumor-associated extrinsic signals such as
IL-6 may be partially driven through APE1.
Within the STAT family of transcription factors, STAT3 is the
first STAT member to be shown to be regulated by APE1. Work
by Li et al elegantly demonstrated using chimera STAT1/STAT3
proteins that STAT3, but not STAT1, is under redox control. [20]
ROS can activate STAT signaling and anti-oxidants can inhibit
this activation. [30] We have previously shown that knocking
down of APE1 in PDAC cells does not increase ROS levels [11],
and therefore its effects on STAT3 DNA-binding activity here
Figure 6. Dual STAT3– APE1 targeting activates Caspase 3 in PDAC cells. Panc-1 and PaCa-2 cells were treated with E3330 (50, 75 mM) and
increasing amounts of STATTIC (A) or S3I-201 (B) and assayed for caspase 3 activity. The graphs represent.3 independent experiments; *, p,0.05, all
compared to STAT3 inhibitor alone at corresponding dose.
doi:10.1371/journal.pone.0047462.g006
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reported cannot be attributed to changes in ROS activity. An
understanding of whether other STAT family members are
regulated by APE1 is important due to their diverse roles in
cellular function including cytokine and growth factor signaling,
differentiation, inflammation, and senescence [31–33], and are
part of ongoing studies.
An exciting finding in this study is the dramatic synergy seen
between APE1 and STAT3 blockade in patient-derived pancreatic
cancer cells. Our study demonstrates the importance of APE1
redox function in regulating STAT3 DNA binding and transcrip-
tional activity (Figure 8). However, APE1 does not regulate only
the DNA binding of STAT3, but also controls the activity of NF-
kB, AP-1, and HIF-1a [1,4]. STAT3, NF-kB, and HIF-1 signaling
contribute to the crosstalk between the tumor and the tumor
microenvironment (TME) [14,34–36]. APE1 also plays an
important role in signaling within the TME through the regulation
of these transcription factors. Therefore, using inhibitors that
target two critical proteins, APE1 and STAT3, we can potentially
disable multiple key pathways in PDAC cell survival, and to
disrupt the integration of signals between tumor and the
microenvironment [37]. This is particularly important in PDAC
as the disease frequently presents with metastatic disease. Our
approach is consistent with the idea of synthetic lethality in which
the pairing of two hits is sufficient to more effectively trigger cancer
cell death, markedly improving the efficacy of single-target agents
[38]. Both of these proteins are upregulated in cancer and
contribute to the resistance of the disease, leaving cancer cells
‘‘addicted’’ to their effector functions. Dual targeting of STAT3
and APE1 is not only efficacious in PDAC; we also observed
significant synergy in glioblastoma cells (Fishel, Kelley, manuscript
Figure 7. STAT3– APE1 dual targeting inhibits PDAC cell migration. Migration assayed via xCELLigence system, treatment with increasing
amounts of S3I-201 (A), STATTIC (B), or E3330 (C). Combination of E3330 (75 mM) with STAT3 inhibitor S3I-201 (D), 50 mM or STATTIC (E), 10 mM
dramatically reduces the cell’s migratory ability. Quantitation of three individual experiments at 8 hr is shown in F and G. * p,0.05, ** p,0.01 using
paired t test comparing inhibitor alone versus combination treatment.
doi:10.1371/journal.pone.0047462.g007
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in preparation). This is especially relevant in brain tumors, where
STAT3 is important in the mesenchymal transformation [39]. As
next steps, we will evaluate STAT3 and APE1 as molecular targets
in xenograft models of human pancreatic cancer. A STAT3-
selective inhibitor is now in a Phase I clinical trial for solid tumors
and preclinical work with E3330 demonstrates its efficacy against
patient-derived PDAC xenografts [4]. These studies will set the
framework for a future clinical study using this dual-targeting
STAT3– APE1 strategy.
The current standard of care for pancreatic cancer (debulking
surgery coupled with chemotherapy and/or radiation) is largely
palliative rather than curative, with rare cases of long-term
regression. The effective targeting of PDAC cells remains a major
clinical challenge. Monotherapies are largely ineffective, therefore
one approach would be to develop two- or multi-hit approaches
[38] targeting signaling pathways that critically regulate PDAC
survival. Strategies, such as the one described here, involving
synthetic lethality, the targeting of critical transcriptional pro-
grams, and molecular effectors of the crosstalk between the tumor
and TME, may offer the most promise for clinical utility against
this dreaded disease. Studies in animal models of PDAC confirm
that dual- or multi-targeting approaches can increase anti-tumor
responses [40,41]. APE1 and STAT3 are upregulated and play
important roles in cancer, suggesting that tumor cells may be
‘addicted’ to their effector functions. In addition to biochemical
and molecular data linking APE1 and STAT3 in PDAC cells, our
studies reveal potent anti-tumor synergism of the combination of
APE1 redox inhibition and STAT3 blockade. Therefore, we
believe that targeting of the APE1– STAT3 molecular axis has
great clinical potential as a novel approach to impair multiple
PDAC cell survival mechanisms.
Materials and Methods
Cell Lines and Patient-derived PDAC Cells
Panc-1 and PaCa-2 were purchased from and authenticated by
ATCC (Manassas, VA). Pa03C, Panc10.05, and Pa02C were
obtained from Dr. Anirban Maitra at The Johns Hopkins
University. [42] All cells were maintained at 37uC in 5% CO2
and grown in DMEM (Invitrogen; Carlsbad, CA) with 10%
Serum (Hyclone; Logan, UT).
Inhibitors
E3330 was synthesized as previously described [3,43], and
STAT3 selective inhibitors S3I-201 [24] and STATTIC [23] were
purchased from Calbiochem.
qRT-PCR Reactions
qRT-PCR was used to measure the mRNA expression levels of
STAT3 and STAT3 downstream target, survivin gene. PaCa-2
and patient-derived lines were treated with increasing amounts of
E3330 for 24-h in media containing 1–2% serum, and total RNA
was extracted from cells using the Qiagen RNeasy Mini kit
(Valencia, CA) according to the manufacturer’s instructions. The
extracted RNA was quantified by a Qubit fluorometer (Invitrogen
Corp, Carlsbad, CA). First-strand cDNA was obtained from RNA
using random hexamers and MultiScribe reverse transcriptase
(Applied Biosystems, Foster City, CA). Quantitative PCR was
Figure 8. Model showing inhibition of STAT3 phosphorylation and nuclear translocation via S3I-201 or STATTIC as well as
inhibition of STAT3 DNA binding via APE1 disruption. TF = Transcription factor.
doi:10.1371/journal.pone.0047462.g008
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performed using Taqman Gene Expression assays and Universal
PCR master mix (Applied Biosystems) in a 7900HT Sequence
detection system (Applied Biosystems). The relative quantitative
mRNA level was determined using the comparative Ct method
using Actin (PaCa-2) or ribosomal protein large, P0 (RPLP0,
patient lines) as the reference gene. [4] The primers for STAT3,
survivin, Actin, and RPLP0 are commercially available (Applied
Biosystems). Experiments were performed in triplicate for each
sample.
Survival, Proliferation, and Synergy Studies
The proliferative capacity of PDAC cells was assessed using the
xCELLigence system (Roche Applied Science, Indianapolis IN)
[4,26] as well as MTS assay as previously described [4].
Combination Index Calculations. PDAC cells were seeded into
96-well plates as described previously, and ED50s of E3330, S3I-
201, or STATTIC on growth were determined using the MTS
assay. Drug interaction was evaluated using CalcuSyn software
(Biosoft, Ferguson, MO), which is based on the Chou-Talalay
method [44].
Transfection of PDAC Cells with APE1 and Scrambled
siRNA
All siRNA transfections were performed as previously described
[10,43,45,46]. STAT3 luciferase assays were conducted on day 3
following knockdown [11].
Western Blot Analysis
For whole cell lysates, cells were harvested, lysed in RIPA buffer
(Santa Cruz Biotechnology; Santa Cruz, CA), and protein was
quantified and electrophoresed. Nuclear and cytoplasmic extracts
were isolated as in [47]. Immunoblotting was performed using the
following antibodies: APE1 (Novus Biologicals; Littleton, CO),
STAT1, STAT3, STAT5, p-STAT1(Y701), p-STAT3(Y705), p-
STAT5 (Y694) (Cell Signaling; Danvers, MA), and tubulin (Sigma
Aldrich) or GAPDH (Santa Cruz).
Electrophoretic Mobility Shift Assay (EMSA)
EMSA were performed as previously described [48] with the
following modifications. For super-shift assay, 6 mg STAT3
antibody (Santa Cruz Biotechnology, Inc, Santa Cruz, CA) was
pre-incubated with 15 mg nuclear extract from PaCa-2 cells
(treated with 50 ng/ml IL-6 for 2 hrs in 2% serum), followed by
1 mg/ul poly(dI-dC) N poly(dI-dC) (Amersham Biosciences, Piscat-
away, NJ) and 0.1 pmol 59HEX-labeled double-stranded oligonu-
cleotide DNA (Midland Certified Reagent Company, Midland,
TX) containing the STAT3 direct repeat consensus sequence (59-
GAT CCT TCT GGG AAT TCC TAG ATC-39) for 15 min.
[49] For the experiment of APE1/STAT3 interaction, purified
APE1 protein was reduced with 2 mM DTT for 10 min and
diluted to a final concentration of 4 mg with 0.4 mM DTT in PBS.
Reduced APE1 was added to 15 mg nuclear extract as above. The
final concentration of DTT in redox reactions was 0.04 mM. For
EMSA with E3330 treatment on nuclear extracts, E3330 was pre-
incubated with purified, reduced APE1 in EMSA reaction buffer
for 30 min, followed by addition of 3 mg nuclear extract.
Apoptosis and Caspase 3 Activation Assays
Apoptosis was assayed 24 h after inhibitor treatment in the
conditions indicated, using Annexin-V/7-AAD [4,50] by flow
cytometry. Activation of Caspase 3 was assessed using the FITC-
conjugated DEVD-FMK inhibitor in permeabilized PDAC cells,
by flow cytometry.
Stable Cell Lines for Reporter Assays
Lentiviral transcriptional reporter vectors pGreenFire- STAT3
and the control pGreenFire-mCMV, (System Biosciences Inc.,
Mountainview, CA) were used to transduce Panc-1 cells, as
previously reported. [4] For overexpression experiments, colonies
were cotransfected with control pcDNA vector, pcDNA-wtAPE1
or pcDNA-C65A-APE1 and Renilla luciferase vector, pRL-CMV
(Promega Corp., Madison, WI), in a 1:10 ratio using Lipofecta-
mine2000. Firefly and Renilla luciferase activities were assayed using
the Dual Luciferase Reporter Assay System (Promega Corp.,
Madison, WI). Transfection experiments were performed in
triplicate and repeated at least three times as independent
experiments.
For STAT3 transactivation experiments with APE1 siRNA,
Panc-1 colonies were transfected with siRNA and assayed for
STAT3 activity. With E3330 treatment, cells were treated for 24 h
in serum free media and then with IL-6 for 6 h. RLU was
normalized to cell viability (MTS assay) as previously described.
[4].
Migration Assay
To assay for migration, we utilized xCELLigence DP cell
invasion and migration (CIM) system. Cells were serum starved for
18 h and then seeded at 86104 in 80 ml of serum-free medium in
the upper chamber with 8 mM pore size while the lower chamber
contained media with 10% serum. Cells were pretreated with the
inhibitors indicated for 2 h, prior to addition to the well. Cell
migration and viability were monitored every hour for 14 h.
Statistics
All data points for vehicle, E3330, STAT3 inhibitor, and
combination treatments were analyzed. Statistical analyses were
performed using the paired t-test, and for the apoptosis
experiments, the one way ANOVA test was used (Sigma Plot
software). Differences between groups were considered significant
if p,0.05. For the analysis of Combination Index (CI) values using
Chou-Talalay method, the Calcusyn program provided the CI
values based on a Dose Effect Analysis. Curves generated using
single agent or combination treatment are scored with an r value,
the linear correlation coefficient. For these experiments, we
required the r value to be above or equal to 0.9. If this
requirement is met, CI values are generated which are quantitative
measures of the degree of drug interaction based on enzyme
kinetic models.
Supporting Information
Figure S1 STAT3 activity is inhibited by APE1 knock-
down, however STAT3 mRNA and protein levels do not
change. Representative experiment of Panc-1 cells transduced
with pGF-STAT3-Luc clones #3 (A) and #9 (B) following
transfection with scrambled or APE1 siRNA (50 nM) and induced
with IL-6 (50 ng/mL, 6 hr). C) Quantitation of Western blot of
total STAT3 protein levels after APE1/Ref-1 knockdown in
PaCa-2 cells. Total STAT3 levels were normalized to Tubulin. D)
The amount of mRNA for STAT3 was analyzed by qPCR, using
RPLP0 as the internal control for patient-derived lines (black bars)
and Actin mRNA as the internal control for PaCa-2 (gray bars).
For the patient-derived lines, the mRNA from three specimens
was measured separately, in triplicate, and then averaged. PaCa-2
was done in three separate experiments in triplicate and the data
averaged. E) Quantitation of Western blot for p-STAT3 levels
following APE1 knockdown in PaCa-2 cells. p-STAT3 levels were
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normalized to total STAT3. Data represent average 6 SD and are
expressed as treated to scrambled (SC) control (n = 4–6).
(TIF)
Figure S2 Inhibition of APE1 redox activity results in
a decrease in STAT3 activity via reporter assay and
target gene expression. A, B) Representative experiment of
STAT3 activity following treatment of Panc-1 clones with APE1
redox inhibitor, E3330. C) Panc-1 cells were transiently trans-
fected with STAT3-Luc construct and cotransfected with a Renilla
vector, pRL-TK. After 16 h, cells were treated with E3330 for
24 h, IL6 (50 ng/mL) for 6 h, and Firefly and Renilla luciferase
activities were assayed using Renilla luciferase activity for
normalization. All transfection experiments were performed in
triplicate and repeated at least 4 times in independent experi-
ments. Data are expressed as Relative Luciferase Units (RLU)
normalized to DMSO, and mean 6 SE are shown. Student’s t
tests were performed; * p,0.05, comparing E3330 versus DMSO.
D) Expression of STAT3 target gene, survivin goes down following
E3330 treatment (24 hr) in PaCa-2 cells (n = 3, avg6SD) via
qPCR.
(TIF)
Figure S3 STAT3-APE1 dual targeting effectively inhi-
bits PDAC cell proliferation. MTS assay was used to
determine cell survival. Both drugs were added and were present
for 72 h. Panc-1 and PaCa-2 were treated with 50 mM E3330.
DMSO was tested as vehicle control. Data shown as mean 6 SE
of at least four independent experiments.
(TIF)
Figure S4 Combination of STAT3 and APE1 inhibitors
inhibit PDAC cell migration. A) Panc-1 cells were serum-
starved overnight. Cells (66105) were plated in duplicate in the
upper chamber CIM plates with or without FN coating. Cells were
also plated in the presence and absence of FBS in the lower
chamber. Readings were taken for 12 h following plating. To
demonstrate that the cells plated for migration shown in Figure 7
were indeed viable and that the migration of live cells was being
monitored, we tested concurrent E-plate assays (B) using the
xCELLigence system or MTS assays (C). Cont = DMSO,
E=E3330, S3I = S3I-201, ST= STATTIC. D) Treatment with
E3330 (75 mM) with STAT3 inhibitor S3I-201 (100 mM),
dramatically reduces the cells’ migratory ability. Quantitation of
three individual experiments at 8 hr is shown in F and G. **
p,0.01 using paired t test comparing S3I-201 alone with
combination treatment.
(TIF)
Table S1 Dual targeting of thioredoxin and STAT3 is
not synergistic in PDAC cells. ED25, 250, and 2759s were
determined using the MTS assay.
(PPTX)
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